Dose Ranging and Dose Frequency of LIPO-102

Phase 2

Completed

• Conditions: Subcutaneous Adipose Tissue Reduction
• Interventions: Drug: Placebo; Drug: LIPO-102

• Registration Number: NCT00918814
• Lead Sponsor: Neothetics, Inc

Brief Summary

Dose Ranging and Dose Frequency of LIPO-102

Detailed Description

Not available

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2009-06-10
• Study First Submitted QC: 2009-06-10
• Study First Posted: 2009-06-11
• Primary Completion: 2010-02
• Study Completion: 2010-02
• Status Verified: 2015-02
• Disposition First Submitted: 2015-02-17
• Disposition First Submitted QC: 2015-02-17
• Last Update Submitted: 2015-02-17
• Disposition First Posted: 2015-03-06
• Last Update Posted: 2015-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

• Male or non pregnant female
• Good general health
• Sufficient abdominal fat for injections
• Signed informed consent

Exclusion Criteria

• Known hypersensitivity to study drugs
• Treatment with an investigational agent within 30 days of first dose

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo
LIPO-102	LIPO-102	LIPO-102

Primary Outcome Measures

Name	Time	Method
Safety: physical examinations, laboratory tests, AE assessment	4 weeks treatment and 4 weeks follow up

Secondary Outcome Measures

Name	Time	Method
Efficacy: change in subcutaneous abdominal adipose tissue thickness	4 weeks treatment and 4 weeks follow up